Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David R. Magnin is active.

Publication


Featured researches published by David R. Magnin.


Bioorganic & Medicinal Chemistry Letters | 2003

Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents

David R. Magnin; Scott A. Biller; John R. Wetterau; Jeffrey A. Robl; John K. Dickson; Prakash Taunk; Thomas Harrity; R. Michael Lawrence; Chongqing Sun; Tammy C. Wang; Janette V. H. Logan; Olga M. Fryszman; Fergal Connolly; Kern Jolibois; Lori Kunselman

A series of newly synthesized phosphonate esters were evaluated for their effects on microsomal triglyceride transfer protein activity (MTP). The most potent compounds were evaluated for their ability to inhibit lipoprotein secretion in HepG2 cells and to affect VLDL secretion in rats. These inhibitors were also found to lower serum cholesterol levels in a hamster model upon oral dosing.


Analytical Biochemistry | 2003

Application of robotics to steady state enzyme kinetics: analysis of tight-binding inhibitors of dipeptidyl peptidase IV

Aiying Wang; Yanting Huang; Prakash Taunk; David R. Magnin; Krishnendu Ghosh; James G. Robertson

Using available commercial robotics and instrumentation, we developed a fully automated and rigorous steady state enzyme kinetic assay for dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5). The automated assay was validated with isoleucyl thiazolidide, a potent inhibitor of DPP IV with K(is)=110nM. Signal window analysis indicated that the assay had a 98% probability of detecting an inhibitor yielding 15% inhibition, with a predicted false positive rate of 0.13%. A mechanistic inhibition version of the automated assay was validated with isoleucyl 4-cyanothiazolidide, a very potent inhibitor of DPP IV. Isoleucyl 4-cyanothiazolidide was a competitive inhibitor of purified porcine DPP IV with K(is)=1 nM. Similar K(is) values were obtained for purified rat DPP IV and for DPP IV activity in human plasma from normal and diabetic donors. The pH dependence of K(is) for isoleucyl 4-cyanothiazolidide yielded a bell-shaped profile, with pK(a)=5.0 and pK(b)=7.6. To date, over 100,000 data points have been generated in profiling targeted compound libraries and in the analysis of tight-binding inhibitors of DPP IV. The data also show that robotic analysis is capable of producing full mechanistic inhibition analysis in a timely fashion to support drug discovery.


Journal of Medicinal Chemistry | 2005

Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri; Jeffrey A. Robl; David A. Betebenner; David R. Magnin; Ashish Khanna; James G. Robertson; Aiying Wang; Ligaya M. Simpkins; Prakash Taunk; Qi Huang; Songping Han; Benoni E. Abboa-Offei; Michael Cap; Li Xin; Li Tao; Effie Tozzo; Gustav Welzel; Donald M. Egan; Jovita Marcinkeviciene; Shu Y. Chang; Scott A. Biller; Mark S. Kirby; Rex A. Parker; Lawrence G. Hamann


Science | 1998

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau; Richard E. Gregg; Thomas Harrity; Cynthia Arbeeny; Michael Cap; Fergal Connolly; Ching-Hsuen Chu; R.J. George; David A. Gordon; Haris Jamil; Kern Jolibois; Lori Kunselman; Shih-Jung Lan; Thomas J. Maccagnan; Beverly Ricci; Mujing Yan; Douglas B. Young; Ying Chen; Olga M. Fryszman; Janette V. H. Logan; Christa L. Musial; Michael A. Poss; Jeffrey A. Robl; Ligaya M. Simpkins; William Allen Slusarchyk; Richard B. Sulsky; Prakash Taunk; David R. Magnin; Joseph A. Tino; R. Michael Lawrence


Archive | 2001

Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

Jeffrey A. Robl; Richard B. Sulsky; David J. Augeri; David R. Magnin; Lawrence G. Hamann; David A. Betebenner


Archive | 1997

Inhibitors of microsomal triglyceride transfer protein and method

Scott A. Biller; John K. Dickson; R. Michael Lawrence; David R. Magnin; Michael A. Poss; Richard B. Sulsky; Joseph A. Tino


Archive | 1996

Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Scott A. Biller; John K. Dickson; R. Michael Lawrence; David R. Magnin; Michael A. Poss; Jeffrey A. Robl; William A. Slusarchyk; Richard B. Sulsky; Joseph A. Tino


Archive | 2000

HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD

Jeffrey A. Robl; Richard B. Sulsky; David R. Magnin


Archive | 1994

α-phosphonosulfonate squalene synthetase inhibitors

David R. Magnin; Scott A. Biller; John K. Dickson; R. Michael Lawrence; Richard B. Sulsky


Archive | 2003

Methods and compounds producing dipeptidyl peptidase iv inhibitors and intermediates thereof

Truc Chi Vu; David B. Brzozowski; Rita Fox; Jollie Duaine Godfrey; Ronald L. Hanson; Sergei V. Kolotuchin; John A. Mazzullo; Ramesh N. Patel; Jianji Wang; Kwok Wong; Jurong Yu; Jason Zhu; David R. Magnin; David J. Augeri; Lawrence G. Hamann

Collaboration


Dive into the David R. Magnin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge